Venus Remedies (BSE:526953) - Share price, News & Analysis

526953 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

526953 Stock Overview

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally.

Rewards

Trading at 79.2% below our estimate of its fair value

Earnings grew by 255.3% over the past year

Risk Analysis

Highly volatile share price over the past 3 months

Large one-off items impacting financial results

Shareholders have been diluted in the past year

Does not have a meaningful market cap (₹3B)

Venus Remedies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Venus Remedies
Historical stock prices
Current Share Price	₹240.10
52 Week High	₹638.50
52 Week Low	₹204.35
Beta	1.45
1 Month Change	-23.00%
3 Month Change	-11.04%
1 Year Change	-23.62%
3 Year Change	637.63%
5 Year Change	155.97%
Change since IPO	533.51%

Shareholder Returns

	526953	IN Pharmaceuticals	IN Market
7D	-0.2%	2.9%	2.1%
1Y	-23.6%	-10.3%	8.6%

Return vs Industry: 526953 underperformed the Indian Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: 526953 underperformed the Indian Market which returned 9.5% over the past year.

Price Volatility

Is 526953's price volatile compared to industry and market?
526953 volatility
526953 Average Weekly Movement	10.1%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	7.0%
10% most volatile stocks in IN Market	9.7%
10% least volatile stocks in IN Market	4.6%

Stable Share Price: 526953 is more volatile than 90% of Indian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 526953's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

Founded	Employees	CEO	Website
1989	837	Ashutosh Jain	https://www.venusremedies.com

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. Venus Remedies Limited was incorporated in 1989 and is based in Panchkula, India.

Venus Remedies Fundamentals Summary

How do Venus Remedies's earnings and revenue compare to its market cap?
526953 fundamental statistics
Market Cap	₹3.21b
Earnings (TTM)	₹756.00m
Revenue (TTM)	₹5.70b

4.2x

P/E Ratio

0.6x

P/S Ratio

Is 526953 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
526953 income statement (TTM)
Revenue	₹5.70b
Cost of Revenue	₹3.65b
Gross Profit	₹2.05b
Other Expenses	₹1.29b
Earnings	₹756.00m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)	56.56
Gross Margin	35.94%
Net Profit Margin	13.26%
Debt/Equity Ratio	9.9%

How did 526953 perform over the long term?

See historical performance and comparison

Valuation

Is Venus Remedies undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 526953 (₹240.1) is trading below our estimate of fair value (₹1154.7)

Significantly Below Fair Value: 526953 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 526953 is good value based on its PE Ratio (4.2x) compared to the Indian Pharmaceuticals industry average (21.5x).

PE vs Market: 526953 is good value based on its PE Ratio (4.2x) compared to the Indian market (20.5x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 526953's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 526953 is good value based on its PB Ratio (0.7x) compared to the IN Pharmaceuticals industry average (2.7x).

Future Growth

How is Venus Remedies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Venus Remedies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Venus Remedies performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

75.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 526953 has a large one-off gain of ₹205.5M impacting its December 31 2021 financial results.

Growing Profit Margin: 526953's current net profit margins (13.3%) are higher than last year (4%).

Past Earnings Growth Analysis

Earnings Trend: 526953 has become profitable over the past 5 years, growing earnings by 75.2% per year.

Accelerating Growth: 526953's earnings growth over the past year (255.3%) exceeds its 5-year average (75.2% per year).

Earnings vs Industry: 526953 earnings growth over the past year (255.3%) exceeded the Pharmaceuticals industry 12.5%.

Return on Equity

High ROE: 526953's Return on Equity (17.4%) is considered low.

Financial Health

How is Venus Remedies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 526953's short term assets (₹2.9B) exceed its short term liabilities (₹1.3B).

Long Term Liabilities: 526953's short term assets (₹2.9B) exceed its long term liabilities (₹464.1M).

Debt to Equity History and Analysis

Debt Level: 526953's net debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: 526953's debt to equity ratio has reduced from 79.2% to 9.9% over the past 5 years.

Debt Coverage: 526953's debt is well covered by operating cash flow (158.3%).

Interest Coverage: 526953 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Venus Remedies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 526953's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 526953's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 526953's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 526953's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: 526953 is not paying a notable dividend for the Indian market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 526953 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure

CEO

Ashutosh Jain (44 yo)

no data

Tenure

₹4,195,958

Compensation

Mr. Ashutosh Jain, B.A., LL B serves as Chief Executive Officer at Venus Remedies Limited. He has been an Executive Director of Venus Remedies Ltd.since May 2007 and serves as its Head of Legal, Regulator...

CEO Compensation Analysis

Compensation vs Market: Ashutosh's total compensation ($USD53.93K) is above average for companies of similar size in the Indian market ($USD38.56K).

Compensation vs Earnings: Ashutosh's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: 526953's management team is considered experienced (2.3 years average tenure).

Board Members

Experienced Board: 526953's board of directors are seasoned and experienced ( 15 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/03/31